There are two surgical options to treat breast cancer: lumpectomy and mastectomy. But there are many more reasons why women choose one over another, says Sarah McLaughlin, M.D., a breast surgical oncologist and chair of the Department of Surgery at Mayo Clinic in Jacksonville, Florida.
Existem duas opções cirúrgicas para tratar o câncer de mama: A lumpectomia e a mastectomia. Mas há muitas outras razões pelas quais as mulheres escolhem uma opção ao invés da outra, conta a Dra. Sarah McLaughlin, cirurgiã oncológica de mama e presidenta do Departamento de Cirurgia da Mayo Clinic em Jacksonville, Flórida.
Hay dos opciones quirúrgicas para tratar el cáncer de mama: La lumpectomía y la mastectomía. Pero hay muchas otras razones por las que las mujeres eligen una opción sobre la otra, dice la Dra. Sarah McLaughlin, cirujana oncológica de mama y presidenta del Departamento de Cirugía de Mayo Clinic en Jacksonville, Florida.
جاكسونفيل، فلوريدا – هناك خياران جراحيان لعلاج سرطان الثدي وهما: استئصال الورم و استئصال الثدي . وهناك العديد من الأسباب التي تجعل المرأة تفضل أحد الخيارين على الآخر، حيث تقول الدكتورة سارة ماكلولين، وهي طبيبة جراحة الأورام ورئيسة قسم جراحة الأورام في مايو كلينك في جاكسونفيل، فلوريدا.
It affects as many as one in 10 people assigned female at birth, and is associated with an increased risk for a few other serious health conditions.
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.
Prostate cancer is the most common non-skin cancer in men in the US, and the 4th most common tumor diagnosed worldwide. As part of its commitment to improving the diagnosis and staging of this disease, Sarasota Memorial Research Institute is proud to announce its participation in the Solar-Stage study sponsored by Curium.
Ludwig Cancer Research congratulates Ludwig Lausanne Director George Coukos on his election to the U.S. National Academy of Medicine (NAM). Among the highest honors issued to clinicians and scientists, membership in the Academy recognizes exceptional achievement and commitment to service in the fields of health and medicine.
UCLA's Dr. Luca Valle was awarded a $2.1 million grant from the U.S. Department of Veterans Affairs to develop new methods to better understand the clinical scope and biological factors that lead to prostate cancer coming back after radiation therapy.
Carlos L. Arteaga, M.D., Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center, and David Mangelsdorf, Ph.D., Chair and Professor of Pharmacology and Professor of Biochemistry, have been elected to the National Academy of Medicine (NAM), one of the highest honors in the fields of health and medicine.
Dr. Deb Schrag, Chair of the Department of Medicine, and Dr. Lorenz Studer, Director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center (MSK), have been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.
A new study has unveiled crucial information about the incidence and risk factors of oral human papillomavirus (HPV) infections among men in the United States, Mexico and Brazil. Moffitt Cancer Center researchers have discovered how often new oral HPV infections occur, the factors influencing their acquisition and the regional variations in infection rates.
A research team led by Dr. Ho Sang Jung of the Advanced Bio and Healthcare Materials Research Division at the Korea Institute of Materials Science has developed an innovative sensor material that amplifies the optical signals of cancer metabolites in body fluids (saliva, mucus, urine, etc.) and analyzes them using artificial intelligence to diagnose cancer.
Laurie J. Kirstein, MD, FACS, a surgical oncologist from Memorial Sloan Kettering Cancer Center (MSK) who specializes in the treatment of breast cancer, will begin a two-year term as the new chair of the American College of Surgeons (ACS) Commission on Cancer (CoC).
Although breast cancer is the most common non-skin cancer diagnosed in women, finding support during treatment and through survivorship can be incredibly challenging. An analysis of posts from breast cancer patients on the popular online forum Reddit found that many breast cancer patients often struggle with several unmet emotional and financial concerns during treatment and long after.
Younger adults with colon cancer tend to be diagnosed at a later stage and have more aggressive types of tumors. Additionally, young patients living with colorectal cancer have long-term, adverse consequences on their lives, which are different from the impact the disease* has on older adults, according to two studies being presented at the American College of Surgeons (ACS) Clinical Congress 2024 in San Francisco, California.
A diagnosis of cancer can take a toll on more than a person’s health. Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston found that financial fallout can follow patients with cancer and their families in the form of bankruptcy, lower credit scores, and other forms of financial challenges years after a cancer diagnosis.
Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, focused on providing additional treatment options for cancer patients, is pleased to announce opening of its trial of 68Ga-EVG321 for patients with small cell lung cancer in the European Union, after receiving approval by the European Medicines Agency (EMA) to start recruitment (EUCT ID # 2024-514584-25-00).
Showing results
1–1 of 1
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
